These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 1446417)

  • 1. Complement and pregnancy: new insights into the immunobiology of the fetomaternal relationship.
    Holmes CH; Simpson KL
    Baillieres Clin Obstet Gynaecol; 1992 Sep; 6(3):439-60. PubMed ID: 1446417
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Complement regulatory proteins at the feto-maternal interface during human placental development: distribution of CD59 by comparison with membrane cofactor protein (CD46) and decay accelerating factor (CD55).
    Holmes CH; Simpson KL; Okada H; Okada N; Wainwright SD; Purcell DF; Houlihan JM
    Eur J Immunol; 1992 Jun; 22(6):1579-85. PubMed ID: 1376264
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alternative complement pathway-mediated myeloid cell cytotoxicity: repertoire of membrane factors participating in regulation of C3 deposition and cytolysis.
    Matsumoto M; Sugita Y; Seya T
    Eur J Immunol; 1991 Aug; 21(8):1787-92. PubMed ID: 1714391
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The complement system in human reproduction.
    Vanderpuye OA; Labarrere CA; McIntyre JA
    Am J Reprod Immunol; 1992; 27(3-4):145-55. PubMed ID: 1384536
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of a hybrid complement regulatory protein, membrane cofactor protein decay accelerating factor on Chinese hamster ovary. Comparison of its regulatory effect with those of decay accelerating factor and membrane cofactor protein.
    Iwata K; Seya T; Ariga H; Nagasawa S
    J Immunol; 1994 Apr; 152(7):3436-44. PubMed ID: 7511647
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Complement regulatory proteins in early human fetal life: CD59, membrane co-factor protein (MCP) and decay-accelerating factor (DAF) are differentially expressed in the developing liver.
    Simpson KL; Houlihan JM; Holmes CH
    Immunology; 1993 Oct; 80(2):183-90. PubMed ID: 7505254
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of decay-accelerating factor on the assembly of the classical and alternative pathway C3 convertases in the presence of C4 or C3 nephritic factor.
    Ito S; Tamura N; Fujita T
    Immunology; 1989 Dec; 68(4):449-52. PubMed ID: 2481642
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mouse complement regulatory protein Crry/p65 uses the specific mechanisms of both human decay-accelerating factor and membrane cofactor protein.
    Kim YU; Kinoshita T; Molina H; Hourcade D; Seya T; Wagner LM; Holers VM
    J Exp Med; 1995 Jan; 181(1):151-9. PubMed ID: 7528766
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Membrane factors responsible for homologous species restriction of complement-mediated lysis: evidence for a factor other than DAF operating at the stage of C8 and C9.
    Shin ML; Hänsch G; Hu VW; Nicholson-Weller A
    J Immunol; 1986 Mar; 136(5):1777-82. PubMed ID: 2419414
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cooperation between decay-accelerating factor and membrane cofactor protein in protecting cells from autologous complement attack.
    Brodbeck WG; Mold C; Atkinson JP; Medof ME
    J Immunol; 2000 Oct; 165(7):3999-4006. PubMed ID: 11034410
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preferential expression of the complement regulatory protein decay accelerating factor at the fetomaternal interface during human pregnancy.
    Holmes CH; Simpson KL; Wainwright SD; Tate CG; Houlihan JM; Sawyer IH; Rogers IP; Spring FA; Anstee DJ; Tanner MJ
    J Immunol; 1990 Apr; 144(8):3099-105. PubMed ID: 1691227
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced reactive lysis of paroxysmal nocturnal hemoglobinuria erythrocytes by C5b-9 does not involve increased C7 binding or cell-bound C3b.
    Rosenfeld SI; Jenkins DE; Leddy JP
    J Immunol; 1985 Jan; 134(1):506-11. PubMed ID: 3964820
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The influence of membrane components on regulation of alternative pathway activation by decay-accelerating factor.
    Mold C; Walter EI; Medof ME
    J Immunol; 1990 Dec; 145(11):3836-41. PubMed ID: 1700997
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assembly of the membrane attack complex promotes decay of the alternative pathway C3 convertase on Neisseria gonorrhoeae.
    Densen P; McRill CM; Ross SC
    J Immunol; 1988 Dec; 141(11):3902-9. PubMed ID: 3141507
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human carcinomas variably express the complement inhibitory proteins CD46 (membrane cofactor protein), CD55 (decay-accelerating factor), and CD59 (protectin).
    Niehans GA; Cherwitz DL; Staley NA; Knapp DJ; Dalmasso AP
    Am J Pathol; 1996 Jul; 149(1):129-42. PubMed ID: 8686736
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complement regulatory molecules on human myelin and glial cells: differential expression affects the deposition of activated complement proteins.
    Koski CL; Estep AE; Sawant-Mane S; Shin ML; Highbarger L; Hansch GM
    J Neurochem; 1996 Jan; 66(1):303-12. PubMed ID: 8522968
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of the effects of activation of the alternative pathway of complement on erythrocytes with an isolated deficiency of decay accelerating factor.
    Holguin MH; Martin CB; Bernshaw NJ; Parker CJ
    J Immunol; 1992 Jan; 148(2):498-502. PubMed ID: 1370313
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Two modes of homologous C3 deposition on Ramos Burkitt's lymphoma cell substrains co-expressing DAF (CD55), CD59, and CR2 (CD21), and on cells lacking them.
    Seya T; Hara T; Okada M; Kojima A; Matsumoto M; Akedo H
    Int Immunol; 1992 Dec; 4(12):1361-71. PubMed ID: 1283697
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evasion of Trypanosoma cruzi from complement lysis.
    Kipnis TL; da Silva WD
    Braz J Med Biol Res; 1989; 22(1):1-16. PubMed ID: 2667667
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aurin tricarboxylic acid self-protects by inhibiting aberrant complement activation at the C3 convertase and C9 binding stages.
    Lee M; Guo JP; McGeer EG; McGeer PL
    Neurobiol Aging; 2013 May; 34(5):1451-61. PubMed ID: 23177218
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.